NCT06959706 2026-04-16
Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of TGW101 in Participants With Advanced Solid Tumors
Tagworks Pharmaceuticals BV
Phase 1 Recruiting
Clinical Trials
2,773 trialsNCT07326800 2026-04-16
MAEva-MCT
Institut de Cancérologie de Lorraine
Phase NA Recruiting
NCT01481532 2026-04-15
Open Label Clinical Trial of Intravenous Crotoxin Part 3
Celtic Biotech Ltd
Phase 1 Not yet recruiting
NCT04452825 2026-04-15
A New Psychotherapy Intervention for Older Cancer Patients
Memorial Sloan Kettering Cancer Center
Phase NA Recruiting
NCT04464226 2026-04-15
Study to Continue Treatment With Darolutamide in Patients Who Have Been Participating in Previous Darolutamide Studies Supported by Bayer
Bayer
Phase 3 Active not recruiting
NCT07005102 2026-04-15
A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
AbbVie
Phase 2/3 Recruiting
NCT07528547 2026-04-15
Peds Ethos
University Health Network, Toronto
Phase NA Recruiting
NCT07532018 2026-04-15
DXP-106
Singlomics (Beijing DanXu) Biopharmaceuticals Co., Ltd.
Phase 1 Recruiting
NCT03768336 2026-04-14
A Stress Management and Resiliency Program for Adolescent and Young Adult Survivors
Massachusetts General Hospital
Phase NA Active not recruiting
NCT03956459 2026-04-14
IQversusMI
Institut Claudius Regaud
Phase NA Completed
NCT04958239 2026-04-14
A Study to Test BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors) and BI 765179 in Combination With Pembrolizumab in Patients With Advanced Head and Neck Cancer
Boehringer Ingelheim
Phase 1 Active not recruiting
NCT05088395 2026-04-14
ALCINA4
Institut Curie
Phase NA Recruiting
NCT05382559 2026-04-14
A Study of ASP3082 in Adults With Advanced Solid Tumors
Astellas Pharma Inc
Phase 1 Recruiting
NCT05611632 2026-04-14
NHS-Galleri
GRAIL, Inc.
Phase NA Active not recruiting
NCT06150157 2026-04-14
A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplasms
Janssen Research & Development, LLC
Phase 1 Recruiting
NCT02908906 2026-04-13
A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, in Participants With Advanced Cancers
Janssen Research & Development, LLC
Phase 1/2 Active not recruiting
NCT03148418 2026-04-13
A Study in Participants Previously Enrolled in a Genentech- and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study (IMbrella A)
Hoffmann-La Roche
Phase 3 Active not recruiting
NCT04606381 2026-04-13
PALOMA
Janssen Research & Development, LLC
Phase 1 Active not recruiting
NCT05120596 2026-04-13
First in Human Study of T3P-Y058-739 (T3P)
T3 Pharmaceuticals AG
Phase 1/2 Recruiting
NCT05155605 2026-04-13
PATHFINDER 2: A Multi-Cancer Early Detection Study
GRAIL, Inc.
Phase NA Active not recruiting
NCT05377554 2026-04-13
Bevonescein for Intra-Operative Nerve Visualization in Head and Neck Surgery
Alume Biosciences, Inc.
Phase 3 Completed
NCT05465161 2026-04-13
StingMark
Centre hospitalier de l'Université de Montréal (CHUM)
Phase NA Recruiting
NCT05862285 2026-04-13
UmbrellaMAX
Hoffmann-La Roche
Phase 3 Recruiting
NCT05879146 2026-04-13
Evaluation of the Response and Non-response of Nirogacestat in Desmoid Tumors- Clinical Study
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT05909202 2026-04-13
A Nature-Based Virtual Reality (VR) Intervention in Family Caregivers of Allogeneic Hematopoietic Stem Cell Transplant (HSCT) Recipients
National Institutes of Health Clinical Center (CC)
Phase NA Completed
NCT06178614 2026-04-13
A Study of JNJ-87890387 for Advanced Solid Tumors
Janssen Research & Development, LLC
Phase 1 Recruiting
NCT06319378 2026-04-13
CAPSI
Section for Affective Disorders; Northern Stockholm Psychiatry
Phase 2 Recruiting
NCT06609473 2026-04-13
CHEF
Dana-Farber Cancer Institute
Phase NA Recruiting
NCT06763770 2026-04-13
Digital Self-Management and Peer Mentoring Intervention
Rutgers, The State University of New Jersey
Phase NA Enrolling by invitation
NCT06941272 2026-04-13
MK-9999-01C
Merck Sharp & Dohme LLC
Phase 1/2 Recruiting
NCT06979596 2026-04-13
OMAHA-015
Merck Sharp & Dohme LLC
Phase 2 Recruiting
NCT07209111 2026-04-13
KANDLELIT-014
Merck Sharp & Dohme LLC
Phase 2 Recruiting
NCT07247110 2026-04-13
A Clinical Study of MK-4716 in People With Certain Solid Tumors (MK-4716-001)
Merck Sharp & Dohme LLC
Phase 1 Recruiting
NCT07515274 2026-04-13
EQUICAP
Centre Leon Berard
Phase NA Not yet recruiting
NCT07525141 2026-04-13
A Study of JNJ-1761981 in Participants With Solid Tumors
Johnson & Johnson Enterprise Innovation Inc.
Phase 1 Not yet recruiting
NCT06555744 2026-04-09
A Study of ZW191 in Participants With Solid Tumors
Zymeworks BC Inc.
Phase 1 Recruiting
NCT07518797 2026-04-09
ASPIRE AI
Rabin Medical Center
Phase NA Not yet recruiting
NCT03366116 2026-04-08
5-aza-4'-Thio-2'-Deoxycytidine (Aza-TdC) in People With Advanced Solid Tumors
National Institutes of Health Clinical Center (CC)
Phase 1 Recruiting
NCT04847466 2026-04-08
Immunotherapy Combination: Irradiated PD-L1 CAR-NK Cells Plus Pembrolizumab Plus N-803 for Subjects With Recurrent/Metastatic Gastric or Head and Neck Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Active not recruiting
NCT05993299 2026-04-08
Study to Evaluate Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Untreated Advanced (Metastatic or Unresectable) Synovial Sarcoma and Myxoid/Round Cell Liposarcoma
USWM, LLC (dba US WorldMeds)
Phase 2 Active not recruiting
NCT06703346 2026-04-08
Study to Evaluate Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Treated Advanced (Metastatic or Unresectable) Synovial Sarcoma or Myxoid/Round Cell Liposarcoma
USWM, LLC (dba US WorldMeds)
Phase 2 Active not recruiting
NCT07284589 2026-04-08
Ultralow Dose PET Imaging of SSTR2 Radiotracer Uptake
Nuclear Imaging Institute
Phase 2 Recruiting
NCT07517666 2026-04-08
GIFTT
Abramson Cancer Center at Penn Medicine
Phase NA Enrolling by invitation
NCT05975073 2026-04-07
A Phase 1/2 Study of Anvumetostat in Combination With IDE397 in Participants With Advanced Methylthioadenosine Phosphorylase (MTAP)-Null Solid Tumors
Amgen
Phase 1/2 Active not recruiting
NCT06593522 2026-04-07
A Phase 2 Study of Anvumetostat in Participants With MTAP-deleted Advanced NSCLC (MTAPESTRY 201)
Amgen
Phase 2 Recruiting
NCT06997029 2026-04-07
A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors
Bristol-Myers Squibb
Phase 1 Recruiting
NCT01445509 2026-04-06
Dasatinib in Combination With Bevacizumab to Treat Advanced Solid Tumors
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT05112965 2026-04-06
An Extension Study in Participants Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella C)
Hoffmann-La Roche
Phase 3 Active not recruiting
NCT05407844 2026-04-06
DeCIDE PC
Wake Forest University Health Sciences
Phase NA Enrolling by invitation
NCT05629234 2026-04-06
ROSY-T
AstraZeneca
Phase 3 Active not recruiting